Patents by Inventor Carolina L. HAASS-KOFFLER

Carolina L. HAASS-KOFFLER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240066009
    Abstract: Stress responses involve corticotropin releasing factor (CRF), the two cognate receptors (CRF1 and CRF2) and the CRF-binding protein (CRFBP). Utilizing a novel cell-based assay, a C-terminal CRFBP fragment [CRFBP(10 kD)] was found to potentiates CRF-intracellular Ca2+ release, demonstrating that CRFBP possesses excitatory roles in addition to the inhibitory role established by the N-terminal fragment of CRFBP [CRFBP(27 kD)]. This interaction was CRF2-specific, as CRF1 responses were not potentiated by CRFBP(10 kD). As there were currently no small molecule ligands available that selectively interact with either CRFBP or CRF2, a cell-based assay was miniaturized, wherein CRFBP(10 kD) was fused as a chimera with CRF2?, that allowed us to a perform a high-throughput screen (HTS) of approximately 350,000 small molecules.
    Type: Application
    Filed: October 13, 2023
    Publication date: February 29, 2024
    Inventor: Carolina L. Haass-Koffler
  • Publication number: 20220273625
    Abstract: Stress responses involve corticotropin releasing factor (CRF), the two cognate receptors (CRF1 and CRF2) and the CRF-binding protein (CRFBP). Utilizing a novel cell-based assay, a C-terminal CRFBP fragment [CRFBP (10 kD)] was found to potentiates CRF-intracellular Ca2+ release, demonstrating that CRFBP possesses excitatory roles in addition to the inhibitory role established by the N-terminal fragment of CRFBP [CRFBP (27 kD)]. This interaction was CRF2-specific, as CRF1 responses were not potentiated by CRFBP (10 kD). As there were currently no small molecule ligands available that selectively interact with either CRFBP or CRF2?, a cell-based assay was miniaturized, wherein CRFBP (10 kD) was fused as a chimera with CRF2?, that allowed us to a perform a high-throughput screen (HTS) of approximately 350,000 small molecules.
    Type: Application
    Filed: March 18, 2022
    Publication date: September 1, 2022
    Inventor: Carolina L. HAASS-KOFFLER
  • Patent number: 11278527
    Abstract: Stress responses involve corticotropin releasing factor (CRF), the two cognate receptors (CRF1 and CRF2) and the CRF-binding protein (CRFBP). Utilizing a novel cell-based assay, a C-terminal CRFBP fragment [CRFBP(10 kD)] was found to potentiates CRF-intracellular Ca2+ release, demonstrating that CRFBP possesses excitatory roles in addition to the inhibitory role established by the N-terminal fragment of CRFBP [CRFBP(27 kD)]. This interaction was CRF2-specific, as CRF1 responses were not potentiated by CRFBP(10 kD). As there were currently no small molecule ligands available that selectively interact with either CRFBP or CRF2, a cell-based assay was miniaturized, wherein CRFBP(10 kD) was fused as a chimera with CRF2?, that allowed us to a perform a high-throughput screen (HTS) of approximately 350,000 small molecules.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: March 22, 2022
    Assignee: BROWN UNIVERSITY
    Inventor: Carolina L. Haass-Koffler
  • Publication number: 20210308107
    Abstract: Stress responses involve corticotropin releasing factor (CRF), the two cognate receptors (CRF1 and CRF2) and the CRF-binding protein (CRFBP). Utilizing a novel cell-based assay, a C-terminal CRFBP fragment [CRFBP(10 kD)] was found to potentiates CRF-intracellular Ca2+ release, demonstrating that CRFBP possesses excitatory roles in addition to the inhibitory role established by the N-terminal fragment of CRFBP [CRFBP(27 kD)]. This interaction was CRF2-specific, as CRF1 responses were not potentiated by CRFBP(10 kD). As there were currently no small molecule ligands available that selectively interact with either CRFBP or CRF2, a cell-based assay was miniaturized, wherein CRFBP(10 kD) was fused as a chimera with CRF2?, that allowed us to a perform a high-throughput screen (HTS) of approximately 350,000 small molecules.
    Type: Application
    Filed: September 4, 2019
    Publication date: October 7, 2021
    Inventor: Carolina L. HAASS-KOFFLER